Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc
(NQ:
XENE
)
41.01
+0.64 (+1.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenon Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
Looking Into Xenon Pharmaceuticals's Return On Capital Employed
June 13, 2022
According to Benzinga Pro data, during Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $8.77 million. Earnings were up 23.06%, but Xenon Pharmaceuticals still reported an overall loss of $19.67...
Via
Benzinga
Recap: Xenon Pharmaceuticals Q1 Earnings
May 10, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Swing Trading Stock Watchlist For April 11 And Beyond
April 10, 2022
The stock market's health is neutral. It is not bad, but it is not great either. I’m willing to take long trades in the stocks discussed if they form valid trade setups and trigger, but I’m not being...
Via
Talk Markets
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Earnings Scheduled For May 10, 2022
May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Via
Benzinga
Swing Trading Stock Watchlist For April 4 And Beyond
April 03, 2022
The stock market's health has improved. That means I have the green light to buy stocks that are forming quality trade setups. Let's dive into what I have been looking at this week.
Via
Talk Markets
Xenon Pharmaceuticals's Return On Capital Employed Overview
March 07, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) brought in sales totaling $3.74 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 65.52%, resulting in...
Via
Benzinga
Recap: Xenon Pharmaceuticals Q4 Earnings
March 01, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Xenon Pharmaceuticals's Earnings: A Preview
February 28, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement....
Via
Benzinga
Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine
January 12, 2022
Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory...
Via
Benzinga
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech
December 29, 2021
For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chi...
Via
Benzinga
Xenon Pharmaceuticals Scores As Epilepsy Results Highlight 'Competitive Profile'
December 03, 2021
More than half of high-dose patients reported a 50% decline in monthly seizures.
Via
Investor's Business Daily
Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment
December 03, 2021
Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal...
Via
Benzinga
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
December 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases...
Via
Benzinga
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
November 28, 2021
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week.
Via
Talk Markets
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
November 28, 2021
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses...
Via
Benzinga
Exposures
COVID-19
Product Safety
Xenon Pharmaceuticals Has a Great Story But Too High a Price
October 29, 2021
XENE stock is a valuable stock market lesson about separating great expectations for stocks from the company's true fundamentals.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021
October 28, 2021
Upgrades For Boot Barn Holdings Inc (NYSE:
Via
Benzinga
Xenon: Heading Toward Phase III With Strong Momentum
October 26, 2021
XENE stock is on solid footing after strong trial results
Via
InvestorPlace
New Clinical Results Make Xenon Pharmaceuticals’ Stock Worthy Again
October 19, 2021
XENE stock deserved to move higher but was stuck for months -- until a game-changing epilepsy treatment put Xenon in the spotlight again.
Via
InvestorPlace
Shares of Xenon Pharmaceuticals Inc. Have Risen Above Previous 52-Week High
October 14, 2021
Shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) traded at a new 52-week high today of $34.80. Approximately 5.5 million shares have changed hands today, as compared to an...
Via
Benzinga
3 Growth Stocks Near 52-Week Highs to Buy Anyway
October 14, 2021
These top performers have what it takes to keep providing outsized gains for patient investors.
Via
The Motley Fool
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
October 10, 2021
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
October 10, 2021
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...
Via
Benzinga
Xenon Pharmaceuticals Raises $300M Via Equity
October 06, 2021
Xenon Pharmaceuticals Inc (NASDAQ: XENE) priced its underwritten public offering of 8.5 million shares and pre-funded warrants to purchase up to 1.7 million shares...
Via
Benzinga
Is Xenon Pharmaceuticals a Good Stock to Buy Now?
October 05, 2021
Despite the big run-up yesterday, there could be enough fuel to push this biotech stock even higher.
Via
The Motley Fool
44 Biggest Movers From Yesterday
October 05, 2021
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of...
Via
Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
October 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.